Zenas BioPharma Enters ~$2B Deal with InnoCare Pharma for Three Autoimmune Product Candidates

Zenas BioPharma Enters ~B Deal with InnoCare Pharma for Three Autoimmune Product Candidates


Shots:

  • InnoCare granted Zenas exclusive global rights to develop, manufacture, & commercialize orelabrutinib for MS & non-oncology indications (excl. Greater China & Southeast Asia), plus rights to an IL-17AA/AF inhibitor outside those regions & a brain-penetrant TYK2 inhibitor globally
  • As per the deal, InnoCare will receive $100M in upfront & near-term milestones, incl. 2026 milestones, ~7M common shares, incl. shares linked to early-2026 milestones, with total potential payments over $2B, plus tiered royalties up to high-teens % on net sales
  • Orelabrutinib will enter P-III trial for secondary progressive MS in Q1’26, while the IND submission & P-I trial for IL-17AA/AF inhibitor & TYK2 inhibitor candidates are planned in 2026

Ref: Zenas BioPharma| Image: Zenas BioPharma & InnoCare Pharma | Press Release

Related News:- Hikma and Celltrion Partner to Commercialize Biosimilars Across the MENA Region

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *